The Enantiomer of ADB-FUBINACA is defined in a 2009 Pfizer patent and has been stated to be a strong agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3. five nM, respectively. ADB-FUBINACA capabilities a carboxamide organization on the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA seems to be made from rational drug design because it differs from AB-FUBINACA handiest via way of means of substituting the isopropyl organization with a tert-butyl organization. An analog of ADB-FUBINACA, ADSB-FUB-187, containing an extra functionalized carboxamide substituent changed into lately stated.
Tỷ Lệ Kèo Bóng đá
Gg88 Work
Printing House
Keonhacai95 Com
Guardian Door And Gate
6623abet
789p
Kendikids.com
Den Haag Mediator
Fo88club